ExceedMDx Genetic Testing offers reliable, accurate, confidential and non-invasive Saliva-Based PCR-based genetic testing for various genetic disorders or inherited diseases. These are traditionally diagnosed in blood/plasma/serum/synovial fluids, however, at ExceedMDX Genetic Testing we perform these tests using a sample of your saliva DNA.
Please note that none of the tests offered by ExceedMDx Genetic Testing are FDA or Health Canada approved tests (please see our regulatory approvals page). However, these tests are conducted confidentially by experienced scientists using the most up-to-date equipment and procedures in an ISO15189 and OLA accredited laboratory.
Step 1: Place your order online, by phone or email.
Step 2 & 3: We ship you a complete package WITHIN 24 HRS. The package contains a saliva DNA collection kit with easy-to-follow instructions. Simply spit a few mL of saliva into the tube, add the DNA preservative and ship back in the provided envelope. The saliva collection vial has a unique bar code that ensures full confidentiality.
Step 4 & 5: Our Scientists will isolate DNA from the saliva perform the ordered genetic test(s) and analyses.
Step 6: In only a few days your test results are ready.
Note that we can do multiple testing from the isolated nucleic acids (DNA & RNA) and consequently if you order a second or a third test your cost will be lower.
Test Currently Available::
The KRAS protein plays an important role in cell signaling and in controlling cell growth. The normal form of the KRAS protein works to recruit and "switch" on/off various proteins that are involved in cell proliferation, survival, and differentiation. The KRAS gene encodes for the KRAS protein, and it has been found that mutations in the KRAS gene can result in an activated form of the KRAS protein that consistently "switches on" the signaling pathway and gives rise to uncontrolled cell division. Uncontrolled cell division can be associated with cancer, and therefore mutations in the KRAS gene are often associated with cancers such as colorectal cancer and non-small cell lung cancer (NSCLC). In addition, certain KRAS mutations render tumours resistant to various forms of anti-cancer therapy. For more information about KRAS, please read here.
The normal form of B-Raf protein works to recruit and "switch" on/off various proteins involved in cell proliferation. The BRAF gene encodes for the B-Raf protein. Mutations in the BRAF gene result in an activated form of the B-Raf protein that consistently "switches on" the signaling pathway, resulting in excessive cell proliferation and cell survival. Mutations in BRAF have been shown to be associated with numerous cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, papillary thyroid carcinoma as well as non-small-cell lung carcinoma. Certain drugs have been developed for the treatment of cancer patients that carry specific mutations of the BRAF gene. For more information about BRAF, please read here.
HER2 (Human Epidermal Growth Factor Receptor 2), also known as neu, is a human protein encoded by the gene ERBB2. HER2 is a protein that is important in stimulating cell growth. Since HER2 plays an important role as a master regulator of different aspects of cellular functions, the level or amount of HER2 proteins in a cell is critical and is tightly controlled. Higher-than-normal amount (known as Amplification or Over-expression) of HER2 causes continuous cell proliferation. Such amplification of HER2 is commonly associated with different forms of cancers including breast cancer, ovarian cancer as well as uterine serous endometrial carcinoma. Several cancer treatments targeting HER2 have been developed. For more information about HER2, please read here.
CYP2C9 and VKORC1
Warfarin is an anticoagulation drug that is used in the prevention of thrombosis. It functions to decrease blood coagulation (blood clotting) by inhibiting a protein known as vitamin K epoxide reductase. Warfarin is commonly applied to prevent or treat various cardiac arrhythmia such as atrial fibrillation as well as pulmonary embolism. Dosing of Warfarin is delicate as its major adverse effect is hemorrhage or bleeding. This is further complicated by its interaction with many commonly used medications as well as various food products. Hence at the initial stage of a Warfarin treatment, the patient may be subjected to multiple blood testing such that a proper Warfarin dosage can be used. The effectiveness of Warfarin treatment is also affected partially by genetic factors. In particular, studies have identified three mutations, known as single nucleotide polymorphisms (SNPs) that are an important determinant of the initial Warfarin dosage. Two of the SNPs are found in the cytochrome P450 enzyme gene CYP2C9, and the third SNP is found in the Vitamin K Epoxide Reductase Complex Subunit 1 (VKORC1). Several reports suggest that using such genetic information may improve the initial estimate of what is a reasonable warfarin dose for individual patients. For more information about Warfarin and the polymophism associated with CYP2C9 and VKORC1, please read here.